Irish Medical Device Start-up Curing Irregular Heart Rhythms Wins the Prestigious ICI Innovation Award

/
DateDec 12 2018
/
Categories,

GALWAY, Ireland, Dec. 12, 2018 /PRNewswire/ — An Irish medical device’s company, AuriGen Medical has won the prestigious Global Innovation Award at the ICI conference in Tel Aviv, Israel. ICI is the premier International Conference for Innovations in Cardiovascular Systems. The Global Innovation award attracted entries from the best medical device and pharmaceutical start-ups from around the world. AuriGen Medical which specialises in the treatment of an irregular heart beat termed atrial fibrillation, is developing the first heart implant to treat both the stroke and heart failure risk associated with this often fatal condition.

Dr. John Thompson, co-founder of AuriGen Medical, winning the ICI Global Innovation Award in Tel Aviv, Israel.
Dr. John Thompson, co-founder of AuriGen Medical, winning the ICI Global Innovation Award in Tel Aviv, Israel.
AuriGen Medical founders Tony O'Halloran and Dr. John Thompson (L-R)
AuriGen Medical founders Tony O’Halloran and Dr. John Thompson (L-R)

“We are extremely honoured to have won this prestigious ICI Award, judged by some of the world’s foremost experts in the field of cardiology,” said Dr John Thompson, CEO of AuriGen Medical Limited. “This validation will help to increase our visibility and accelerate the development of AuriGen’s technology, which will deliver hope to the countless patients with this condition.”

Everyday over 30 million patients suffer with atrial fibrillation, a condition which can lead to stroke, dementia, heart failure and death. Unfortunately for the majority of atrial fibrillation patients with persistent longstanding disease, the current treatment options are routinely ineffective, which results in billions in direct healthcare costs.

The AuriGen Device incorporates unique patented sensor and implant technology. This technology is designed to quickly and safely isolate the source of atrial fibrillation and filter blood clots, preventing them from transferring to the brain, thereby reducing the risk of stroke.

AuriGen Medical is no stranger to success having recently been ranked first out of almost 1,300 EU Horizon 2020 funding applications. The pioneering technology has secured a €2.5 million cash injection from the European Union’s €80 billion research and innovation programme.

Note to editor:

AuriGen Medical Ltd is a privately held, Galway (Ireland) based medical technology company specialising in the field of cardiology.  The company designs and develops products to treat chronic heart conditions. Our initial focus is the development of a medical device which treats the stroke and arrythmia risk associated with persistent longstanding atrial fibrillation.